Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial
Clinical Oncology · 2026-09 · 57 · 104293
DOI: 10.1016/j.clon.2026.104293 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Oncology, 2026-09. Verfasst von Y Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, 450008, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Chemoradiotherapy, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Health Commission of Henan Province.
Abstract (Originalsprache)
AIM: This clinical investigation evaluated the efficacy and safety of the immune checkpoint inhibitor camrelizumab administered with concurrent chemoradiotherapy in patients with locally advanced cervical cancer. MATERIALS AND METHODS: This prospective trial enrolled patients aged 18-75 years with previously untreated cervical cancer classified as stage IIB to IVA according to the 2018 International Federation of Gynecology and Obstetrics system. Patients received intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) external-beam radiotherapy combined with three-dimensional brachytherapy, cisplatin chemotherapy, and camrelizumab 200 mg every 3 weeks for up to 1 year. Progression-free survival (PFS) was the primary endpoint; overall survival (OS) was a secondary exploratory endpoint of interest. Secondary endpoints also included treatment safety. RESULTS: A total of 50 patients were enrolled between February 2021 and July 2022. The majority had International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIIC1r/IIIC2r (70.0%) disease. The median age was 50.2 years (range, 30-65), and the median follow-up duration was 46.3 months (range, 37.5-55.4 months). The median PFS was not reached, and the 36-month PFS rate was 84.0% (95 % confidence interval [CI]: 73.8-94.2 %) The 36-month OS rate was 100%, and the median OS was not reached. Exploratory subgroup analyses for PFS and OS based on PD-L1 status and FIGO 2018 stage demonstrated favorable survival outcomes across subgroups, with no statistically significant difference between the PD-L1 positive and negative subgroups (log-rank P > 0.05). Treatment-related adverse events occurred in 96% of patients, although grade 3 or higher events were infrequent (0-18.0%), most commonly hematologic toxicity and enteritis. Immune-related adverse events (irAEs) occurred in 92.0% (46/50) of patients, and grade 3 or higher immune-related events occurred in 4.0% (2/50), including one case of conjunctivitis (2.0%, 1/50) and one case of lateral rectus muscle paralysis (2.0%, 1/50). No treatment-related mortalities or cases of irreversible organ damage were observed. An exploratory analysis examining the association between the total EQD2 radiation dose (≥85 Gy vs
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, 450008, China.
- Department of Gynecology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, 450008, China. Electronic address: chenghuijunchjcc@126.com.
- Drug Safety Evaluation Research Center, School of Pharmacy, Zhengzhou University, Zhengzhou, 450001, China. Electronic address: fengxuejiandrfxj@163.com.
Förderung
- Health Commission of Henan Province
Zitieren
APA
Xiao, Y., Yang, L., Yu, X., Cheng, H. J., & Feng, X. J. (2026). Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial. Clinical Oncology, 57, 104293. https://doi.org/10.1016/j.clon.2026.104293
Vancouver
Xiao Y, Yang L, Yu X, Cheng HJ, Feng XJ. Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial. Clinical Oncology. 2026;57:104293. doi:10.1016/j.clon.2026.104293
BibTeX
@article{Xiao2026,
author = {Xiao, Y and Yang, L and Yu, X and Cheng, H-J and Feng, X-J},
title = {Efficacy and Safety of Camrelizumab Combined with Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Phase II Single-Arm Clinical Trial},
journal = {Clinical Oncology},
year = {2026},
volume = {57},
pages = {104293},
doi = {10.1016/j.clon.2026.104293}
}
EUVIMED